UBS Group Reaffirms Sell Rating for Oscar Health (NYSE:OSCR)

Oscar Health (NYSE:OSCR - Get Free Report)'s stock had its "sell" rating restated by investment analysts at UBS Group in a report released on Tuesday, MarketBeat Ratings reports. They currently have a $11.00 target price on the stock, down from their prior target price of $15.00. UBS Group's price objective suggests a potential downside of 27.48% from the company's current price.

A number of other equities analysts also recently weighed in on OSCR. Piper Sandler downgraded shares of Oscar Health from an "overweight" rating to a "neutral" rating and set a $14.00 price target on the stock. in a research note on Monday. Wall Street Zen cut shares of Oscar Health from a "buy" rating to a "hold" rating in a report on Sunday, June 8th. Raymond James Financial lowered shares of Oscar Health from an "outperform" rating to a "market perform" rating in a research note on Tuesday, June 24th. Wells Fargo & Company cut Oscar Health from an "equal weight" rating to an "underweight" rating and cut their price target for the company from $16.00 to $10.00 in a report on Friday. Finally, Barclays initiated coverage on shares of Oscar Health in a research report on Wednesday, July 2nd. They issued an "underweight" rating and a $17.00 price target for the company. Five equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. Based on data from MarketBeat.com, Oscar Health currently has an average rating of "Reduce" and a consensus target price of $12.92.

Oscar Health Price Performance

NYSE:OSCR opened at $15.17 on Tuesday. Oscar Health has a 1 year low of $11.20 and a 1 year high of $23.79. The business has a 50 day simple moving average of $16.35 and a 200-day simple moving average of $14.90. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of 54.17 and a beta of 1.90. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.88 and a quick ratio of 0.88.

Oscar Health (NYSE:OSCR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.09. Oscar Health had a net margin of 1.22% and a return on equity of 10.59%. The business had revenue of $3 billion for the quarter, compared to the consensus estimate of $2.87 billion. During the same period last year, the firm posted $0.62 earnings per share. The company's revenue was up 42.2% compared to the same quarter last year. Equities analysts forecast that Oscar Health will post 0.69 EPS for the current year.

Insider Activity

In related news, Director Elbert O. Jr. Robinson sold 25,000 shares of the company's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $16.43, for a total value of $410,750.00. Following the completion of the transaction, the director directly owned 64,512 shares of the company's stock, valued at approximately $1,059,932.16. This represents a 27.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 25.11% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in Oscar Health by 348.7% during the fourth quarter. JPMorgan Chase & Co. now owns 10,360,529 shares of the company's stock worth $139,246,000 after buying an additional 8,051,379 shares in the last quarter. BIT Capital GmbH grew its stake in shares of Oscar Health by 5,711.6% in the fourth quarter. BIT Capital GmbH now owns 4,473,853 shares of the company's stock worth $60,129,000 after purchasing an additional 4,396,872 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of Oscar Health by 50.7% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 11,835,000 shares of the company's stock valued at $159,062,000 after purchasing an additional 3,983,325 shares during the last quarter. Nuveen LLC acquired a new position in Oscar Health during the 1st quarter worth approximately $29,684,000. Finally, Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Oscar Health by 51.4% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 6,335,862 shares of the company's stock worth $85,154,000 after acquiring an additional 2,151,256 shares during the last quarter. 75.70% of the stock is currently owned by institutional investors.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.